Antimicrobial Use Guidelines (AMUG) version 21 - UW Health

Amph/AMPHOTERICIN B LIPID COMPLEX Collaborative Study Group. Clin Infect Dis2000;31(5):1155-63.32. Winston DJ. Hathorn JW. Schuster MG. Schiller GJ. Territo MC. A multicenter,randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy offebrile neutropenic patients with cancer. Am J Med 2000;108(4):282-9.33. Boogaerts M. Winston DJ. Bow EJ. Garber G. Reboli AC. Schwarer AP. Novitzky N.Boehme A. Chwetzoff E. De Beule K. Itraconazole Neutropenia Study Group.Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate asempirical antifungal therapy for persistent fever in neutropenic patients with cancer whoare receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. AnnIntern Med 2001;135(6):412-22.34. Persistent fever in patients with neutropenia. N Engl J Med 2002;346(4):222-4.35. Walsh TJ. Pappas P. Winston DJ. Lazarus HM. Petersen F. Raffalli J. Yanovich S. StiffP. Greenberg R. Donowitz G. Schuster M. Reboli A. Wingard J. Arndt C. Reinhardt J.Hadley S. Finberg R. Laverdiere M. Perfect J. Garber G. Fioritoni G. Anaissie E. Lee J.National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazolecompared with liposomal amphotericin B for empirical antifungal therapy in patients withneutropenia and persistent fever. N Engl J Med 2002;346(4):225-34.36. Powers JH. Dixon CA. Goldberger MJ. Voriconazole versus liposomal amphotericin B inpatients with neutropenia and persistent fever. N Engl J Med 2002;346(4):289-90.37. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, CornelyOA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomalamphotericin B for empirical antifungal therapy in patients with persistent fever andneutropenia. N Engl J Med 2004;351:1391-402.38. Klastersky J. Antifungal therapy in patients with fever and neutropenia – more rationaland less empirical? N Engl J Med 2004;351:1445-6.39. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: Concern forresistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol2004;42:4419-31.40. Goodman JL. Winston DJ. Greenfield RA. Chandrasekar PH. Fox B. Kaizer H. ShadduckRK. Shea TC. Stiff P. Friedman DJ. et al. A controlled trial of fluconazole to preventfungal infections in patients undergoing bone marrow transplantation. N Engl J Med1992;326(13):845-51.41. Slavin MA. Osborne B. Adams R. Levenstein MJ. Schoch HG. Feldman AR. Meyers JD.Bowden RA. Efficacy and safety of fluconazole prophylaxis for fungal infections aftermarrow transplantation--a prospective, randomized, double-blind study. J Infect Dis1995;171(6):1545-52.42. Marr KA. Seidel K. White TC. Bowden RA. Candidemia in allogeneic blood and marrowtransplant recipients: evolution of risk factors after the adoption of prophylacticfluconazole. J Infect Dis 2000;181(1):309-16.43. Winston DJ. Maziarz RT. Chandrasekar PH. Lazarus HM. Goldman M. Blumer JL. LeitzGJ. Territo MC. Intravenous and oral itraconazole versus intravenous and oralfluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-celltransplant recipients. A multicenter, randomized trial. Ann of Intern Med2003;138(9):705-13.44. Bow EJ. Laverdiere M. Lussier N. Rotstein C. Cheang MS. Ioannou S. Antifungalprophylaxis for severely neutropenic chemotherapy recipients: a meta analysis ofrandomized-controlled clinical trials. Cancer 2002;94(12):3230-46.45. vanBurik JA, Ratanathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, WallDa, Heimenz JW, Satoi Y, Lee JM, Walsh TJ, Narional Institute of Allergy and InfectiousDisease Mycoses Study Group. Micafungin versus fluconazole for prophylaxis againstinvasive fungal infections during neutropenia in patients undergoing hematopoietic stemcell transplantation. Clin Infect Dis 2004;39:1407-1416.46. Courtney R, Sudhakar P, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, andtolerability of oral posaconazole administered in single and multiple doses in healthadults. Antimicrob Agents Chemother 2003;47:2788-2795.